Diptoindonesin G Antagonizes AR Signaling and Enhances the Efficacy of Antiandrogen Therapy in Prostate Cancer

Through co-targeting the androgen receptor (AR) signaling, Diptoindonesin G robustly improved the efficacy of HSP90 inhibitors and enzalutamide in both human prostate cancer cells and in vivo xenograft mouse model.